Tech Company Financing Transactions
Naurex Funding Round
Naurex, operating out of Evanston, scored $25 million in funding from Baxter Ventures, Shire Pharmaceuticals and Takeda Ventures.
Transaction Overview
Company Name
Announced On
5/7/2014
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company will use the proceeds to continue development of its most promising drug candidates.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1801 Maple Ave. 4300
Evanston, IL 60201
USA
Evanston, IL 60201
USA
Phone
Website
Email Address
Overview
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Norbert Riedel
Chief Financial Officer
James Schulz
Chief Medical Officer
Ronald Burch
Chief Scientific Officer
Joseph Moskal
VP - Bus. Development
Ashish Khanna
Browse more venture capital transactions:
Prev: 5/7/2014: BlueStacks venture capital transaction
Next: 5/8/2014: FieldLens venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs